Europska Unija - hrvatski - EMA (European Medicines Agency)

viatris healthcare limited - imikimod - condylomata acuminata; keratosis; keratosis, actinic; carcinoma, basal cell - antibiotici i kemoterapeutici za dermatološku uporabu - imiquimod cream is indicated for the topical treatment of :external genital and perianal warts (condylomata acuminata) in adults. small superficial basal cell carcinomas (sbccs) in adults. clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (aks) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.

Europska Unija - hrvatski - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - idursulfase - mukopolisaharidoza ii - drugi gastrointestinalni trakt i metabolizam, lijekovi, - elaprase je indiciran za dugotrajno liječenje bolesnika sa hunter sindrom (mukopolisaharidozom ii, gpp ii). heterozigotne ženke nisu proučavane u kliničkim ispitivanjima.

Europska Unija - hrvatski - EMA (European Medicines Agency)

zoetis belgium sa - oclacitinib maleata - agenti za dermatitis, isključujući kortikosteroide - psi - - treatment of pruritus associated with allergic dermatitis in dogs. - treatment of clinical manifestations of atopic dermatitis in dogs.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ceva sante animale - dinotefuran, pyriproxyfen, permetrin - permetrin, kombinacije - psi - prevencija i liječenje invazija buha (ctenocephalides feliz i ctenocephalides канис). prevencija i liječenje zaraze grinje (rhipicephalus sanguineus, dermacentor reticulatus, иксодовых ricinusovog). prevencija ugriza od komaraca (Флеботомусов щитовками), komarci (tako ga zovu jer pipiens, komarac желтолихорадочный) i muha (stomoxys calcitrans). tretman komaraca (aedes aegypti) i stabilan muha (stomoxys calcitrans) zaraza.

Europska Unija - hrvatski - EMA (European Medicines Agency)

zentiva k.s. - Рилузол - amiotrofna lateralna skleroza - ostali lijekovi protiv živčanog sustava - riluzole zentiva indicirana je produžiti život ili vrijeme mehaničke ventilacije u bolesnika s amiotrofične lateralne skleroze (als). clinical trials have demonstrated that riluzole zentiva extends survival for patients with als. stopa preživljavanja je bila definirana kao bolesnika, koji su bili živi, ne интубирован za mehaničku ventilaciju i traheotomije-besplatno. nema dokaza, da Рилузол tinktura ima ljekovito utjecaj na motoričke funkcije, funkciju pluća, фасцикуляции, snaga mišića i motoričke simptome. Рилузол Зентива nisu pokazala da se učinkovite u kasnijim fazama als. sigurnost i učinkovitost Рилузол Зентива samo je studirao u als. tako Рилузол Зентива ne smije primijeniti u bolesnika s bilo koji drugi oblik bolesti motornog neurona.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

abbott laboratories d.o.o. koranska 2 10000 zagreb -

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

abbott laboratories d.o.o. koranska 2 10000 zagreb -

Europska Unija - hrvatski - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - multipli mijelom - antineoplastična sredstva - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Europska Unija - hrvatski - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. pogledajte odjeljke 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

bracco imaging s.p.a., via egidio folli 50, milano, italija - dimeglumingadobenat - otopina za injekciju - 334 mg/ml - urbroj: 1 ml otopine za injekciju sadrži 529 mg dimeglumingadobenata (što odgovara 334 mg (0,5 mmol/ml) gadobenatne kiseline i 195 mg meglumina)